We aimed to evaluate the efficacy and safety of combining vemurafenib (BRAF inhibitor) with a programmed death 1 (PD-1) inhibitor in patients with BRAF V600-mutant melanoma in China…Advanced BRAF V600-mutant melanoma patients treated with vemurafenib and anti-PD-1 antibody at Sun-Yat Sen University Cancer Center between June 2017 and May 2019 were retrospectively analyzed. Vemurafenib was administered with a 4–6-weeks run-in period followed by PD-1 blockade (pembrolizumab or toripalimab) combined with vemurafenib until disease progression or unacceptable toxicity...In total, 39 patients were included. All the patients had tumor shrinkage. The objective response rate was 64.1% (95% CI, 48.7–79.4) and the complete response was observed in 8 (20.5%; 95% CI, 7.7–33.3) patients. The median progression-free survival (PFS) was 13.2 months (95% CI: 8.2–18.2)...Vemurafenib combined with anti-PD-1 antibody had promising clinical activity and manageable safety.